How Stiripentol Reduces Neuronal Excitability
Stiripentol lowers brain excitability primarily by allosterically enhancing GABAA receptor activity, increasing chloride influx and hyperpolarizing neurons to suppress seizures. Unlike many antiseizure drugs that directly bind GABAA sites, it acts at a distinct modulatory site, boosting GABA's effects without competing for the primary binding pocket.[1]
Why Its Mechanism Differs from Benzodiazepines and Barbiturates
Benzodiazepines bind the alpha-gamma interface of GABA_A receptors for positive allosteric modulation, while barbiturates target the beta subunit pore for gating enhancement. Stiripentol binds uniquely at the beta(+)/alpha(-) transmembrane interface, stabilizing the open channel state selectively for β2/β3-containing receptors abundant in the hippocampus and cortex—key Dravet syndrome seizure hotspots.[2][3]
Role of GABA Transaminase Inhibition
Stiripentol uniquely inhibits GABA transaminase (GABA-T), the enzyme that breaks down GABA into succinic semialdehyde. This elevates extracellular GABA levels by 50-100% in rodent models, amplifying tonic inhibition without altering GABA synthesis or release. Few other antiseizure drugs combine this with direct receptor modulation.[4]
Impact on Glutamatergic Transmission
It indirectly curbs glutamate release by enhancing GABAergic tone on glutamatergic terminals, reducing excitatory postsynaptic currents by up to 40% in hippocampal slices. This dual GABA boost (receptor + metabolic) sets it apart from pure receptor agonists like benzodiazepines, which lack metabolic effects.[5]
Why It's Effective in Dravet Syndrome
In Dravet, SCN1A mutations cause GABA interneuron dysfunction and network hyperexcitability. Stiripentol's broad-spectrum action restores inhibition despite low Nav1.1 sodium channels, outperforming drugs reliant on sodium blockade. Clinical trials show 70% seizure reduction when added to clobazam, partly due to synergistic GABA-T inhibition.[6]
Potential Limitations and Off-Target Effects
High-fat meals boost bioavailability 2-3x via delayed gastric emptying, but it weakly inhibits CYP enzymes (CYP2C19, CYP3A4), raising levels of co-drugs like clobazam. No major pro-excitatory risks noted, though sedation occurs in 20-30% of patients.[7]
[1] PubMed: Stiripentol: pharmacology and clinical efficacy
[2] Nature: Structural basis of stiripentol potentiation
[3] Epilepsia: GABA_A receptor subunit selectivity
[4] J Pharmacol Exp Ther: GABA-T inhibition kinetics
[5] Neuropharmacology: Glutamate modulation
[6] Lancet Neurol: Dravet trial data
[7] FDA Label: Diacomit (stiripentol)